EPA and statin in the prevention of cardiovascular events
In patients with acute myocardial infarction (AMI), early combined administration (within the first 24 hours) of eicosapentaenoic acid (EPA) and a statin after a percutaneous coronary intervention reduces inflammation and ventricular arrhythmia more effectively than administration of a statin alone. A prospective, open, randomised trial, blinded for assessors, was conducted on 241 patients with acute coronary syndrome (ACS) to determine whether early treatment with EPA reduces adverse cardiovascular events (cardiovascular-related death, non-fatal stroke, non-fatal myocardial infarction and revascularisation). The patients were randomly assigned to receiving 2 mg/day of pitavastatin with or without 1800 mg/day of EPA, within 24 h of a percutaneous coronary intervention.
After one year, early combined administration of EPA and a statin after a primary percutaneous coronary intervention significantly reduced adverse cardiovascular events after ACS (P=0.02). Notably, cardiovascular-related deaths were also reduced (p=0.04).